You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Review: non-steroidal anti-inflammatory drugs are slightly better than paracetamol for reducing pain in osteoarthritis

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: non-steroidal anti-inflammatory drugs are slightly better than paracetamol for reducing pain in osteoarthritis

https://doi.org/10.1136/ebm.9.6.180

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Wegman A, van der Windt D, van Tulder M, et al. Nonsteroidal antiinflammatory drugs or acetaminophen for osteoarthritis of the hip or knee? A systematic review of evidence and guidelines. J Rheumatol 2004;31:344–54.
    OpenUrlAbstract/FREE Full Text

    
 
 Q In patients with osteoarthritis (OA) of the knee or hip, are non-steroidal anti-inflammatory drugs (NSAIDs) more effective than paracetamol (acetaminophen) for reducing OA related pain or disability?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Rheumatology ★★★★☆☆☆☆☆

    METHODS

    Embedded ImageData sources:

    Medline, EMBASE/Excerpta Medica, and the Cochrane Database (all up to December 2001), and bibliographies of relevant articles.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) (full reports published in any language) that compared an NSAID with paracetamol in patients with OA of the hip or knee, and measured relevant outcomes. Study quality was assessed using the internal validity criteria of the Amsterdam-Maastricht Consensus List for Quality Assessment with emphasis on adequate procedures for randomisation and sufficient blinding (maximum score 11 points).

    Embedded ImageOutcomes:

    overall change in pain and disability (physician assessment), pain on motion …

    View Full Text

    Footnotes

    • For correspondence: Dr D van der Windt, Institute for Research in Extramural Medicine, Amsterdam, The Netherlands. Dawm.vanderwindtvumc.nl

    • Source of funding: Leo Pharma.